Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESPAMA: WADA Prohibited Substances Excretion Study
NCT04757532Phase 1Completed
- Sponsor
- Parc de Salut Mar
- Start
- Dec 2020
- Primary completion
- Mar 2021
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of bupropion, anastrozole, testosterone cypionate, danazol and chlorthalidone in major depressive disorder (MDD), breast cancer, Hypogonadism and 2 more (5 arms), sponsored by Parc de Salut Mar. Primary endpoints: Urine concentration of bupropion metabolites, Urine concentration of anastrozole metabolites and 3 more. Started Dec 2020; status: completed.
02
Drugs
bupropionanastrozoletestosterone cypionatedanazolchlorthalidone
03
Conditions
major depressive disorder (MDD)breast cancerHypogonadismendometriosishypertension (HTN)
Beyond the preview
Go deeper on NCT04757532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04757532.